Aaron Feldman

Aaron is a multi-disciplinary chemist, specializing in nucleic acids. He received his PhD in Chemistry from Scripps Research in La Jolla, working in the lab of Floyd E. Romesberg on the engineering of a semi-synthetic strain of E. coli, publishing 13 papers in journals like Nature, PNAS, and JACS, as well as multiple patents. His work helped build the foundation for the protein therapeutics platform at Synthorx Inc (acquired by Sanofi in 2019). He then moved into the world of next-gen sequencing, leading a nucleotide chemistry group at Omniome Inc (acquired by Pacific Biosciences in 2021). Today, Aaron is helping to bring enzymatic DNA synthesis to market by leading the chemistry efforts at Ansa Bio.